Olanzapine: Difference between revisions
(Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: Zyprexa, Zydis ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== *Dr...") |
Elcatracho (talk | contribs) |
||
| (21 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: | *Type: [[Antipsychotic]], second generation | ||
*Dosage Forms: | *Dosage Forms: tablets, solution, suspension | ||
*Routes of Administration: | *Routes of Administration: oral, intramuscular | ||
**Oral rapidly dispersible wafer considered bioequialent to tablet form <ref>Montgomery W, Treuer T, Karagianis J, Ascher-Svanum H, Harrison G. Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties. Patient Prefer Adherence. 2012;6:109-125. doi:10.2147/PPA.S27344</ref> | |||
*Common Trade Names: Zyprexa, Zydis | *Common Trade Names: Zyprexa, Zydis | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Acute agitation (associated with schizophrenia or bipolar disorder): Short-acting IM injection: | |||
**initial dose: 10 mg IM (consider lowering to 5 or 7.5 mg depending on clinical factors), additional dose of 10 mg IM maybe considered. Allowed 2 hours after the first dose and 4 hours after the second dose to evaluate response (maximum dose: 30 mg/day). | |||
**Special risk patients: consider lowering dose to 2.5 mg IM in patients who are debilitated, who have risk of hypotension or who maybe more pharmacodynamically sensitive to olanzapine. | |||
*Schizophrenia: Oral | |||
**Initial dose 5-10 mg once daily, increase to 10 mg daily by the first week, adjust by 5 mg daily at 1-week interval (maximum dose: 20 mg daily), maintenance dose: 10-20 mg daily. | |||
**Special risk patient: Initial dose: 5 mg once daily in patients who are debilitated, who have risk of hypotension or who maybe more pharmacodynamically sensitive to olanzapine. | |||
*Bipolar I (acute mixed or manic episode): Oral | |||
**Monotherapy: Initial dose: 10-15 mg once daily, increase by 5 mg daily with interval >24 hours, maintenance dose: 5-20 mg daily (maximum dose: 20 mg daily). | |||
**Combination therapy with lithium or valproate: Initial dose 10 mg daily (dose range: 5-20 mg daily) | |||
*Depression: Oral | |||
**Depression associated with bipolar disorder (in combination with fluoxetine): Initial dose: 5 mg once daily, adjust to dose range of 5-12.5 mg daily. | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Schizophrenia: Adolescent ≥13 years: Oral: Initial dose: 2.5-5 mg once daily, adjust by 2.5-5 mg daily to target dose of 10 mg daily (dose range: 2.5-20 mg daily). | |||
*Bipolar I (acute or mixed manic episode): Adolescent ≥13 years: Oral: Initial dose: 2.5-5 mg once daily, adjust by 2.5-5 mg daily to target dose of 10 mg daily (dose range: 2.5-20 mg daily). | |||
*Depression associated with bipolar I disorder (in combination with fluoxetine: Children and adolescent 10 to 17 years: Oral: Initial dose: 2.5 mg once daily in the evening, adjust if needed, safety for dose >12 mg daily of olanzapine and >50 mg daily of fluoxetine has not been studied. | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]: Olanzapine is excreted into breast milk. Brest-feeding is not recommended by manufacturer. | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
* | *No dosage adjustment is necessary, not removed by dialysis. | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
* | *Use with caution, in combination with fluoxetine, initial dose of olanzapine should not exceed 2.5-5 mg daily. | ||
==Contraindications== | ==Contraindications== | ||
| Line 24: | Line 37: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Orthostatic hypotension (3%-20%) | |||
*[[Extrapyramidal reaction]] | |||
*Akathisia | |||
*Parkinsonian-like syndrome | |||
*Increase serum prolactin | |||
*Increase serum AST, ALT, GGT and bilirubin | |||
*Accidental injury | |||
*Personality disorder | |||
===Common=== | ===Common=== | ||
*Drowsiness | |||
*Dizziness | |||
*Insomnia | |||
*Weight gain | |||
*Increase appetite | |||
*Xerostomia | |||
*[[Constipation]] | |||
*Dyspepsia | |||
*[[Weakness]] | |||
*Abnormal gait | |||
*Increase uric acid | |||
*Bruise | |||
*Tremor | |||
*Limb pain | |||
*[[Back pain]] | |||
*Arthralgia | |||
*Rhinitis | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: Oral and short-acting IM: children 10 to 18 years ~37 hours, adult ~30 hours, 1.5 times greater in elderly. | ||
*Metabolism: | *Metabolism: Liver: CYP1A2, CYP2D6, 40% removed via first pass metabolism | ||
*Excretion: | *Excretion: Urine (~70%), feces (30%) | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Potent antagonism of serotonin 5-HT<sub>2A</sub> and 5T<sub>2C</sub>, Dopamine<sub>1-4</sub>, histamine H<sub>1</sub> and α<sub>1</sub>-adrenergic recepter | |||
==Comments== | ==Comments== | ||
==See Also== | ==See Also== | ||
*[[Antipsychotics]] | |||
*[[Antipsychotic toxicity]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Psychiatry]] | |||
Latest revision as of 04:09, 7 March 2021
Administration
- Type: Antipsychotic, second generation
- Dosage Forms: tablets, solution, suspension
- Routes of Administration: oral, intramuscular
- Oral rapidly dispersible wafer considered bioequialent to tablet form [1]
- Common Trade Names: Zyprexa, Zydis
Adult Dosing
- Acute agitation (associated with schizophrenia or bipolar disorder): Short-acting IM injection:
- initial dose: 10 mg IM (consider lowering to 5 or 7.5 mg depending on clinical factors), additional dose of 10 mg IM maybe considered. Allowed 2 hours after the first dose and 4 hours after the second dose to evaluate response (maximum dose: 30 mg/day).
- Special risk patients: consider lowering dose to 2.5 mg IM in patients who are debilitated, who have risk of hypotension or who maybe more pharmacodynamically sensitive to olanzapine.
- Schizophrenia: Oral
- Initial dose 5-10 mg once daily, increase to 10 mg daily by the first week, adjust by 5 mg daily at 1-week interval (maximum dose: 20 mg daily), maintenance dose: 10-20 mg daily.
- Special risk patient: Initial dose: 5 mg once daily in patients who are debilitated, who have risk of hypotension or who maybe more pharmacodynamically sensitive to olanzapine.
- Bipolar I (acute mixed or manic episode): Oral
- Monotherapy: Initial dose: 10-15 mg once daily, increase by 5 mg daily with interval >24 hours, maintenance dose: 5-20 mg daily (maximum dose: 20 mg daily).
- Combination therapy with lithium or valproate: Initial dose 10 mg daily (dose range: 5-20 mg daily)
- Depression: Oral
- Depression associated with bipolar disorder (in combination with fluoxetine): Initial dose: 5 mg once daily, adjust to dose range of 5-12.5 mg daily.
Pediatric Dosing
- Schizophrenia: Adolescent ≥13 years: Oral: Initial dose: 2.5-5 mg once daily, adjust by 2.5-5 mg daily to target dose of 10 mg daily (dose range: 2.5-20 mg daily).
- Bipolar I (acute or mixed manic episode): Adolescent ≥13 years: Oral: Initial dose: 2.5-5 mg once daily, adjust by 2.5-5 mg daily to target dose of 10 mg daily (dose range: 2.5-20 mg daily).
- Depression associated with bipolar I disorder (in combination with fluoxetine: Children and adolescent 10 to 17 years: Oral: Initial dose: 2.5 mg once daily in the evening, adjust if needed, safety for dose >12 mg daily of olanzapine and >50 mg daily of fluoxetine has not been studied.
Special Populations
- Pregnancy Rating: C
- Lactation risk: Olanzapine is excreted into breast milk. Brest-feeding is not recommended by manufacturer.
Renal Dosing
- No dosage adjustment is necessary, not removed by dialysis.
Hepatic Dosing
- Use with caution, in combination with fluoxetine, initial dose of olanzapine should not exceed 2.5-5 mg daily.
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Orthostatic hypotension (3%-20%)
- Extrapyramidal reaction
- Akathisia
- Parkinsonian-like syndrome
- Increase serum prolactin
- Increase serum AST, ALT, GGT and bilirubin
- Accidental injury
- Personality disorder
Common
- Drowsiness
- Dizziness
- Insomnia
- Weight gain
- Increase appetite
- Xerostomia
- Constipation
- Dyspepsia
- Weakness
- Abnormal gait
- Increase uric acid
- Bruise
- Tremor
- Limb pain
- Back pain
- Arthralgia
- Rhinitis
Pharmacology
- Half-life: Oral and short-acting IM: children 10 to 18 years ~37 hours, adult ~30 hours, 1.5 times greater in elderly.
- Metabolism: Liver: CYP1A2, CYP2D6, 40% removed via first pass metabolism
- Excretion: Urine (~70%), feces (30%)
Mechanism of Action
- Potent antagonism of serotonin 5-HT2A and 5T2C, Dopamine1-4, histamine H1 and α1-adrenergic recepter
Comments
See Also
References
- ↑ Montgomery W, Treuer T, Karagianis J, Ascher-Svanum H, Harrison G. Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties. Patient Prefer Adherence. 2012;6:109-125. doi:10.2147/PPA.S27344
